We investigated the mechanisms by which corticosteroids affect atherosclerosis. Male New Zealand White rabbits were injected with 0.125 mg dexamethasone (n = 10) or vehicle (control group, n = 10). Both groups were fed a 1% cholesterol diet for 8 weeks. Although the dexamethasone-treated animals exhibited a greater degree of hvperlipidemia, they exhibited significantly less atherosclerotic plaque of the aortic surface than control animals (7.8% versus 47.2%). Immunofluorescence study of the aortic plaque specimens showed that dexamethasone administration reduced both macrophages and T lymphocytes. In vitro, dexamethasone suppressed the proliferation and differentiation of U937 cells and inhibited uptake and degradation of 0-very low density lipoproteins by mouse peritoneal macrophages. These findings suggest that dexamethasone suppresses the development of atherosclerosis in the aorta of rabbits by inhibiting recruitment and proliferation of macrophages and the formation of foam cells in plaques. {Arteriosclerosis and Thrombosis 1993;13:892-899) 
anti-inflammatory agents have been evaluated in the treatment of atherosclerosis. 3 Anti-inflammatory drugs, including corticosteroids, have been found to suppress the development of atherosclerosis in both cholesterolfed New Zealand White rabbits 4^ and Watanabe heritable hyperlipidemic rabbits. 6 In a different model of experimental atherosclerosis, dexamethasone inhibited both the leukocyte accumulation and intimal thickening induced by cuff sheathing in the rabbit carotid artery; indomethacin, a cyclcoxygenase inhibitor, had little effect. 7 However, the mechanisms by which corticosteroids exert an inhibitory effect on atherosclerotic plaque formation remain to be elucidated. In particular, the phenomenon of reduced plaque formation in the presence of enhanced hyperlipidemia in corticosteroidtreated, cholesterol-fed rabbits 34 has not been explained. Since monocyte-derived macrophages are thought to play an important role in atherogenesis, we attempted to clarify the mechanism of action of corticosteroids by focusing on the effect of corticosteroid treatment on macrophages. We investigated the effects of dexamethasone on plasma lipoproteins and on the distribution of macrophages and T lymphocytes in plaques of cholesterol-fed rabbits. We also conducted in vitro experiments using monocyte/macrophage-like cells.
Methods

Animal Experiments
Twenty male New Zealand White rabbits weighing 2.2-2.5 kg were divided into two groups: a dexamethasone-treated group (n = 10) and a control group (n = 10). Both groups were fed a 1% cholesterol diet for 8 weeks. During those 8 weeks, the dexamethasone-treated group received daily injections of 0.125 mg i.m. (0.050-0.057 mg/kg body wt) of dexamethasone (Banyu Pharmaceutical Co., Tokyo) in 0.1 mL of vehicle. The control group received only vehicle, which contained sodium bisulfate (0.5 mg/mL), methyl p-hydroxybenzoate (1.5 mg/mL), propyl p-hydroxybenzoate (0.2 mg/ mL), and creatinine (8 mg/mL). Blood was sampled at 4-week intervals for the determination of hemoglobin, serum total cholesterol (TC), total protein, and glucose. Very low density lipoprotein (VLDL, d< 1.006 g/mL) was separated from plasma by ultracentrifugation, 8 and the concentrations of protein, TC, and triglyceride (TG) were measured. TC/TG was calculated as an index of the composition of lipids in VLDL. After 8 weeks, all rabbits were killed by injection of sodium pentobarbital (150 mg i.v.); the whole aorta was removed and incised longitudinally. The aortic surface involved by plaque was traced within 12 hours of removal of the aortas, assessed quantitatively by planimetry with a computer, and expressed as the proportion (percent) of the area of plaque involvement to that of the entire area of the aorta.
All experiments were conducted in accordance with institutional guidelines for animal studies.
Immunofluorescence Study of Aortic Specimens
Small portions were obtained from the aortic base from two representative animals in each group with the highest or the second highest serum cholesterol level, snap-frozen in liquid nitrogen, and stored at -80°C until studied. Frozen tissues were cut into 2-/xm sections with a cryostat. Sections were fixed with acetone at room temperature for 10 minutes and air-dried. After being washed with 0.01 mol/L phosphate-buffered saline (PBS), the sections were incubated for 20 minutes with an optimal concentration of the mouse monoclonal anti-macrophage immunoglobulin M (IgM) antibody (HAM-56, Enzo Diagnostics, New York). The sections were washed three times with PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated rabbit antibody against mouse IgM (HAM-56). Similarly, to stain the T lymphocytes in plaques, the sections were first incubated with goat anti-rabbit T-lymphocyte polyclonal antibody (CL-8800, Cedarlane Laboratories, Hamby, Canada) and then stained with FITC-conjugated rabbit anti-goat IgG. In addition, small portions from the aortic base were fixed in 10% formalin, embedded in paraffin, and stained with hematoxylin and eosin.
Proliferation and Differentiation of U937
Proliferation H]thymidine (TdR) incorporation. The U937 cultures, which had been growth arrested and incubated for 48 hours in RPMI 1640 with 0.5% FCS, were incubated in a growth medium containing 10"' to 10~6 mol/L dexamethasone and incubated for 24 hours. Aliquots (1 mL) with a density of 4x10* cells/mL were incubated with 3.7 kBq/mL of pH]TdR (NEN Research Products, Boston) for 2 hours at 37*C. The cells were then washed twice with Dulbecco's PBS, and the radioactivity in trichloroacetic acid (TCA, Katayama Chemical, Osaka, Japan)-insoluble fractions was measured.
Differentiation of U937byphorbol esters. The U937 cell line is a well-characterized representative of monocytic cells that, on stimulation with differentiation-inducing agents such as phorbol esters, mature along the monocytic pathway. 9 When stimulated by phorbol 12-myristate 13-acetate (PMA, Sigma), these cells adhere to plastic and exhibit macrophage-like characteristics. 10 To assess the effect of dexamethasone on the PMAinduced differentiation, we counted the number of the adherent cells 10 after they were cultured for 72 hours with 10~9 to lfT 6 mol/L dexamethasone and lfT 9 mol/L PMA dissolved in dimethyl sulfoxide (DMSO, Katayama Chemical). The final concentration of DMSO in the incubation medium was 0.1% (vol/vol). Percentage of adherent cells was calculated as number of adherent cells divided by number of nonadherent cells plus adherent cells times 100 (%).
In each experiment, the viability of U937 cells was determined by trypan blue dye exclusion. Results are given as the average of triplicate incubations.
Binding, Uptake, and Degradation of fi-VLDL by Mouse Peritoneal Macrophages
Unstimulated ddY mice weighing 25-30 g were anesthetized with ethyl ether in air, and peritoneal cells were harvested in Dulbecco's PBS." Cells were collected by centrifugation (400g, 10 minutes) and washed once with Dulbecco's modified Eagle's medium (DMEM, Nissui Pharmaceutical Co.). Aliquots (1 mL) were dispensed into 12-well dishes (Corning 25815, Corning, N.Y.) in DMEM containing 20% (vol/vol) FCS and then incubated in a humidified CO 2 (5%) incubator at 37°C for 2 hours. After being washed to remove the nonadherent cells, the monolayers were incubated with or without 10~7 mol/L dexamethasone for 36 hours at 37°C in DMEM containing 20% FCS and then used in experiments." Each dish contained about 70-90 jig cell 12 The specific activity of 125 I-£-VLDL ranged from 20 to 40 cpm/ng iodine monochloride protein. Treatment with 15% TCA consistently precipitated >97% of the radioactivity. An average of 3.5% radioactivity was present in the lipid, as determined by chloroform/ methanol extraction. After the medium was replaced by DMEM containing 0.3% bovine serum albumin (BSA, Sigma) with or without 10" 7 mol/L dexamethasone, the cells were incubated with 123 I-/3-VLDL for 5 hours. The total cellular content (cellular uptake) of 125 I-/3-VLDL in the peritoneal macrophages was measured. 13 The proteolytic degradation of 125 I-/3-VLDL by the cells was determined by assaying the amount of the l25 I-labeled, TCA-soluble material excreted into the medium from the cells. 13 For the binding study, the cells were incubated with 125 I-£-VLDL at 4°C for 2 hours. Each dish was washed six times with 2 mL of buffer containing 50 mmol/L tris(hydroxymethyl)aminomethane chloride (pH 7.4), 0.15 mol/L NaCl, and 6 mg BSA. The cells were then dissolved in 1 mL of 0.1N NaOH and incubated for 1 hour at room temperature. The entire sample was assayed to determine the radioactivity associated with the cells. Each data point represents the average of duplicate incubations. The protein content of the lipoproteins and cell extracts was determined by the method of Lowry et al. 15 
Other Assays
Serum levels of cholesterol, 16 TG, 17 total protein, and glucose were determined by established procedures. Data are expressed as mean±SD. Statistical significance was determined by Student's t test, with the probability level set at/?<0.05.
Results
Macroscopic and Microscopic Findings
As illustrated in Figures 1A and IB, dexamethasone suppressed plaque involvement of the aortic surface by 83% compared with control rabbits (/?<0.001). Microscopic study of plaques from the aortic base showed a markedly raised intima with proliferation of foam cells in control rabbits. In dexamethasone-treated rabbits, the lesions consisted of fewer layers of foam cells.
Immunofluorescence Study
Immunofluorescence microscopic study using antimacrophage monoclonal antibody (HAM-56) showed clusters of positively stained cells in atherosclerotic plaques of the control animals ( Figure 2A ). There was a marked decrease in these cells in the dexamethasonetreated rabbits ( Figure 2B) . Similarly, aortic specimens stained with anti-T-rymphocyte polyclonal antibody (CL-8800) showed some T lymphocytes in the plaques of the control rabbits but almost no T lymphocytes in aortic specimens from dexamethasone-treated animals ( Figures 2C and 2D ).
Body Weight, Organ Weight, and Laboratory Parameters
The serum TC level in the dexamethasone-treated group was more than twice that of the control group (Table 1) : l,804±612 mg/dL (control) versus 4,089± 1,181 mg/dL (dexamethasone-treated) (p<0.001). Serum total protein levels in the dexamethasone-treated group were significantly higher than in the control group (p<0.001). Hemoglobin and serum glucose did not differ significantly between the two groups. Baseline body weights were similar in both groups: 2,266 ±163 g (control) versus 2,266±111 g (dexamethasone-treated). At autopsy, the body weight of the dexamethasone-treated animals was significantly (p<0.001) decreased compared with control, indicating that the dexamethasone-treated rabbits gained less weight during the experimental period. The weights of major organs did not differ between the groups, with the exception of the adrenal gland, which was significantly (/?<0.01) smaller in the dexamethasone-treated group.
Analysis of VLDL Fractions
Analysis of VLDL fractions revealed a significant increase in protein (p<0.01), TC (/7<0.01), and TG (/><0.001) in the dexamethasone-treated gToup compared with the control group at 4 weeks ( Table 2 ). In the dexamethasone-treated group, the TC/TG was significantly lower (p<0.001) at 4 weeks but was significantly higher (p<0.05) at 8 weeks.
Proliferation and Differentiation of U937 Cells
The U937 cells used in this study consistently showed a viability of >95%, as determined by trypan blue dye exclusion. As shown in Figure 3 , top panel, dexamethasone at concentrations of 10" 8 to 10~6 mol/L significantly (1(T 8 mol/L, p<0.05; 10" 7 to 10" 6 mol/L, /?<0.001) suppressed the increase in number of U937 cells after 48 hours of culture. Cell viability was >90% after treatment with 10"' to 10~6 mol/L dexamethasone, similar to cell viability in the control group (Figure 3 6 mol/L dexamethasone for 24 hours showed a significantly (p<0.05) decreased DNA synthesis (Figure 3, bottom) . Again, cell viability did not differ between the control and dexamethasone-treated cells. These results suggest that dexamethasone suppressed the proliferation of U937 cells without causing significant toxic effects.
The U937 cells incubated with 10~9 mol/L PMA for 72 hours showed a sixfold increase (from 4.9% to 29.9%) in adherence, as measured by percent adherence to plastic dishes ( Figure 4 ). Dexamethasone at concentrations of 10" 7 to 10" 6 mol/L significantly (/?<0.001) reduced the percentage of adherent U937 cells. When the viability of residual nonattached cells was examined, the PMA-treated cells showed a slight decrease after 72 hours of incubation: 95.2% (0.1% DMSO control) versus 91.6% (0.1% ethanol control with PMA). The dexamethasone-treated cells showed at least 88.5% viability (10" 7 mol/L), indicating that dexamethasone treatment did not produce any significant decrease in the viability of nonattached cells.
Binding, Uptake, and Degradation of 125 I-B-VLDL by Mouse Peritoneal Macrophages
The effects of dexamethasone at 10~7 mol/L on 125 I-/3-VLDL binding, uptake, and degradation as a function of ligand concentration appear in 
Discussion
The mechanism by which corticosteroids inhibit dietinduced atherosclerosis in rabbits has not been established. Our results showed that dexamethasone reduced the development of grossly visible atherosclerotic plaques by an average of 83% in cholesterol-fed rabbits, despite the development of a greater degree of hyperlipidemia in treated animals. These findings are consistent with previous reports. 4 -6 Less plaque formation in the presence of more highly elevated serum cholesterol levels contradicts the assumption that the severity of atherosclerosis is proportional to serum cholesterol levels. We performed lipoprotein analysis, an immunofluorescence study of plaques, and in vitro experiments to examine the effects of dexamethasone on U937 cells and mouse peritoneal macrophages in an attempt to explain this paradox. Our analysis of VLDL fractions indicated that VLDL concentration was increased in dexamethasone-treated animals, but there was no con- sistent difference in TC/TG of VLDL fractions between the two groups throughout the experiment.
Macrophages specifically and saturably bind glucocorticoids via their cytosol receptors, 18 which, in turn, modulate numerous macrophage functions. 19 Our in vitro results using the monocyte/macrophage cell line U937 showed that dexamethasone suppressed not only proliferation of these cells but also their PMA-induced differentiation without significantly affecting cell viability. These observations are consistent with previous 
1% DMSO and ethanoL Percent of adherent cells is expressed as number of adherent cells divided by number of nonadherent cells plus adherent cells times 100 (%). Each point represents the mean of six incubations. The viability of residual nonadherent cells is expressed as the average of triplicate determinations. O, Cell viability without dexamethasone; 9, cell viability with dexamethasone. ***p<0.001 (vs. 0).
reports. 10 ' 20 It has been shown that proliferating macrophages exist in atherosclerotic lesions from cholesterolfed rabbits. 21 The systemic administration of corticosteroids has induced a prolonged monocytopenia in blood and a characteristic reduction of mononuclear phagocytes at the site of inflammation during steroid treatment. 22 Moreover, corticosteroids have also been found to reduce monocyte chemotaxis in response to various inducers. 23 Together with these findings, our immunofluorescence study data suggest that dexamethasone inhibited the recruitment and proliferation of monocyte-derived macrophages in the aortic wall.
Although dexamethasone did not alter the binding of 125 1-B-VLDL to mouse peritoneal macrophages, it reduced 125 I-/3-VLDL uptake and degradation. Related studies conducted under somewhat different experimental conditions have shown that exposure of cultured fibroblasts and arterial smooth muscle cells to physiological concentrations of hydrocortisone (4.1 x 10~8 mol/ L), 24 of cultured human monocyte-derived macrophages to dexamethasone, 23 and of cultured human fibroblasts to serum from glucocorticoid-treated patients 26 reduces their capacity to degrade low density lipoprotein (LDL). Recent reports indicate that uptake of B-VLDL is mediated by the LDL receptor, 27 -29 suggesting that, in our experiments, dexamethasone suppressed the degradation of B-VLDL via the LDL pathway. Our results with dexamethasone are similar to those in an earlier report 24 showing that hydrocortisone reduced LDL uptake and degradation by cultured human fibroblasts without affecting binding. using LDL. When Henze et al measured the net LDL uptake to cultured fibroblasts and arterial smooth muscle cells by trypsinization, they found that hydrocortisone reduced the interaalization of LDL. In addition to an enhanced hepatic production or secretion of VLDL caused by dexamethasone administration, 30 these alterations in /3-VLDL metabolism in macrophages may play a role in the dexamethasone-induced enhancement of hyperlipidemia. It is conceivable that, despite the enhanced hyperlipidemia induced by a high-cholesterol diet, dexamethasone suppressed macrophages that would be expected to take up and degrade excess /3-VLDL in the aortic wall, leading to a decrease in the formation of foam cells. However, a toxic effect of dexamethasone on macrophages can be excluded, since we observed no difference in the amount of cell protein or the number of cells (data not shown).
These observations suggest that dexamethasone enhances the accumulation of /3-VLDL in plasma but suppresses the recruitment of monocyte-derived macrophages to the aortic wall, as evidenced by the presence of fewer macrophages in the plaques of the dexamethasone-treated rabbits. In addition, this agent may have inhibited foam cell formation via a reduction in the uptake of /3-VLDL by macrophages.
The T lymphocytes frequently found in association with macrophages in plaques 31 may be involved in atherogenesis. 2 Immunofluorescence study in our experiments showed that dexamethasone greatly diminished T lymphocytes in plaques. Since corticosteroids suppress the production of interleukin-1 by macrophages, 32 they may thus exert an inhibitory effect on T-cell accumulation in plaques.
Corticosteroids have been used to treat a variety of chronic diseases, such as rheumatoid arthritis and systemic lupus erythematosus, over long periods. Nevertheless, there is little information on the effects of corticosteroids on atherosclerosis. In humans, retrospective studies, including pathological data obtained at autopsy, suggested that these agents, through their hyperlipidemic action, adversely affected atherogenesis. 33 - 35 The inconsistency between such reports and our experimental findings raises the question of whether corticosteroids may exert a different action on atherogenesis in humans versus cholesterol-fed rabbits. Although we have no data to answer that question, recent studies 25 using cultured human monocyte-derived macrophages have shown that dexamethasone stimulates acetyl-LDL receptor activity. If this were true in vivo, dexamethasone would augment the scavenger receptor activity of the macrophages for the denatured LDL, which is thought to play a central role in atherogenesis, 36 and would thus accelerate atherosclerosis in humans. Therefore, differing atherogenic lipoproteins in humans and cholesterol-fed rabbits may account for the different response of macrophages to corticosteroid treatment.
The dose of dexamethasone (0.050-0.057 mg/kg) used in our animal experiment is comparable to that administered clinically. However, when administered in vivo for long periods as in this experiment, dexamethasone causes a variety of side effects, including growth retardation or atrophy of adrenal glands ( Table 1 ), indicating that the antiatherogenic effect of dexamethasone cannot be practically applied in the clinical setting. Nonetheless, our data show that, irrespective of the presence of hyperlipidemia, atherosclerotic plaque formation can be suppressed by modulating the function of macrophages. Recently, the suppression of aortic atherosclerosis by purified rabbit interferon was observed in cholesterol-fed rabbits 37 in which, interestingly, interferon administration did not change the serum lipid levels but decreased the number of foam cells of macrophage origin in the atherosclerotic lesions. This result, as well as our findings, suggests that approaches other than the lowering of serum cholesterol that may affect the inflammatory aspects of atherosclerosis may protect against atherogenesis.
In conclusion, our observations suggest that dexamethasone suppresses the recruitment and proliferation of macrophages and the formation of foam cells in atherosclerotic lesions, thereby inhibiting the development of aortic atherosclerosis in cholesterol-fed rabbits. These findings may provide new insights into the pharmacological control of atherosclerosis.
